Maroun Khoury, CSO , Cells for Cells, Santiago, Chile
Santiago (Chile), 20 June 2020 – Cells for Cells, a cell therapy- and tissue engineering- focused company, announces that the U.S. Patent and Trademark Office (USPTO) has granted the company a US patent covering the AUTOMATED FABRICATION OF LAYER-BY-LAYER TISSUE ENGINEERED COMPLEX TUBES (US20180304502).
The novel approach comprises the use of a robot that can achieve precise geometrical, mechanical and biological personalization of tissue-like conduits thanks to the controlled and automated deposition at high resolution of biomaterials, nanofibers and cells in a unique and rapid one-step fabrication procedure. The personalized tubes manufactured through this patented technology possess a multilayer structure that resembles the anatomy of tissue conduits that are replaced in the treatment of a multitude of different pathologies. Examples of applications that can benefit from these novel tissue conduits include arteries and veins, urethra and intestinal tissues.
Typically, the production of Tissue Engineered Products requires multiple steps that go from scaffold fabrication to cell seeding, maturation in bioreactors, and, ultimately, packaging, making the manufacturing of such solutions a long and inefficient process, which is, moreover, expensive and difficult to standardize. “These manufacturing issues have been pointed out in the last years as the main drawbacks that are keeping advanced tissue engineered medical solutions commercially unfeasible and away from the clinical reality”, says Juan Pablo Acevedo, the lead investigator of the graft project, at Cells for Cells.
The approach, which has been highlighted in prominent peer-reviewed scientific journals (Akentjew et al., Nature Communications, 2019), allows for scalable tissue conduits to be ready to implant in less than an hour with guaranteed standardization and quality.
This solved for the first time technical and commercial issues of the field and makes possible the quick manufacturing of very-needed tissue conduits near the point of treatment.
“This is one of the most exciting projects harbored in our company portfolio. We have a multidisciplinary team with experience in tissue engineering, cell therapy, biomaterials and robotics, tapping in the brainpower of each other to bring these tubular grafts closer to patients”, discloses, Maroun Khoury, CSO of Cells for Cells.
The preclinical results in large animal models are looking positive, but nothing should be assumed and further evidence are being generated to fully assess the potential of the personalized vascular graft technology before initiating its testing in a first-in-human clinical trial.
- Akentjew, T.L., Terraza, C., Suazo, C. et al.Rapid fabrication of reinforced and cell-laden vascular grafts structurally inspired by human coronary arteries. Nat Commun 10, 3098 (2019). https://doi.org/10.1038/s41467-019-11090-3